Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2OTHER_GOV 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 16Other solid neoplasm 9Tumor-Agnostic 3Sarcoma 3Gynecologic 3Gastrointestinal 3Breast 3NET 2Endocrine 2Other hematologic neoplasm 1CNS 1

Conditions

Neuroendocrine Tumors 2Neoplasms 2Stomach Neoplasms 1Sarcoma 1Mesothelioma 1Glioblastoma 1Gastro-enteropancreatic neuroendocrine tumor 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

Everolimus 18lutetium Lu 177 dotatate 9lanreotide 8surufatinib 7Octreotide 7pasireotide 5amino-acid, glucose, and electrolyte solution 5Sunitinib 5Temozolomide 4Data Collection 4pembrolizumab 3177Lu-octreotide, DOTA(0)-Tyr(3)- 3tislelizumab 2fosbretabulin 2arginyllysine 2anlotinib 2Paclitaxel 2PM 01183 2Lutetium-177 2Lutetium 2Irinotecan 2Injections 2Carboplatin 264Cu-SARTATE 23-Iodobenzylguanidine 2toripalimab 1telotristat ethyl 1taxane 1repotrectinib 1pralsetinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × PM 01183 × NET × Clear all
NCT02611024 2025-07-09

Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors

PharmaMar

Phase 1/2 Completed
316 enrolled
CNSEndocrineGastrointestinalGynecologicNETOther solid neoplasmSarcomaThoracic

Gastro-enteropancreatic neuroendocrine tumor, Carcinoma, Ovarian Epithelial, Glioblastoma, Mesothelioma, Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Neuroendocrine Tumors

NCT01970540 2020-03-09

Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors

PharmaMar

Phase 1 Completed
122 enrolled 19 charts
EndocrineNET

Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡